Environmental risk factors for inflammatory bowel diseases: Evidence based literature review

World Journal of Gastroenterology

Volumn 22, Issue 27, 2016, Pages 6296-6317

  Abegunde, Ayokunle T ^a   Muhammad, Bashir H ^a   Bhatti, Owais ^a   Ali, Tauseef ^a  

^a OKLAHOMA CITY UNIVERSITY   (United States)

Author keywords

Environmental factors; Exposomes; Inflammatory bowel disease

Indexed keywords

ANTIBIOTIC AGENT; FOOD ADDITIVE; FOOD ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; VITAMIN D; ANTIINFECTIVE AGENT; FAT INTAKE; VACCINE;

AIR POLLUTION; ANUS FISTULA; APPENDECTOMY; BREAST FEEDING; CARBOHYDRATE INTAKE; CHRONIC INFLAMMATION; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DIETARY FIBER; DISEASE COURSE; DRUG MEGADOSE; DYSBIOSIS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ENVIRONMENTAL SANITATION; FAT INTAKE; GENETIC RISK; HUMAN; HYGIENE HYPOTHESIS; INDUSTRIALIZATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; PARASITOSIS; PATHOGENESIS; PNEUMONIA; PROTEIN INTAKE; RELAPSE; REVIEW; SLEEP DISORDER; SMOKING; SOCIOECONOMICS; STRESS; THERAPY WITH HELMINTHS; ULCERATIVE COLITIS; VACCINATION; VIRUS INFECTION; VITAMIN D DEFICIENCY; WATER POLLUTION; EVIDENCE BASED MEDICINE; HYGIENE; INFECTION; INFLAMMATORY BOWEL DISEASES; MEAT; MENTAL STRESS; RISK FACTOR; SANITATION; SLEEP; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA;

AIR POLLUTION; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APPENDECTOMY; BREAST FEEDING; CONTRACEPTIVES, ORAL; DIETARY FATS; DIETARY FIBER; DYSBIOSIS; ENVIRONMENTAL EXPOSURE; EVIDENCE-BASED MEDICINE; FOOD ADDITIVES; GASTROINTESTINAL MICROBIOME; HUMANS; HYGIENE; HYGIENE HYPOTHESIS; INDUSTRIAL DEVELOPMENT; INFECTION; INFLAMMATORY BOWEL DISEASES; MEAT; RISK FACTORS; SANITATION; SLEEP; SMOKING; SOCIAL CLASS; STRESS, PSYCHOLOGICAL; VACCINES; VITAMIN D DEFICIENCY; WATER POLLUTION;

EID: 84978531660     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i27.6296     Document Type: Review

References (214)

1. Russell RK, Satsangi J. Does IBD run in families? Inflamm Bowel Dis 2008; 14. Suppl 2: S20-S21 [PMID: 18816757 DOI: 10.1002/ibd.20573]
2. Ek WE, D'Amato M, Halfvarson J. The history of genetics in inflammatory bowel disease. Ann Gastroenterol 2014; 27: 294-303 [PMID: 25331623]
3. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603 [PMID: 11385576]
4. Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipocs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004; 10: 404-409 [PMID: 14760767]
5. Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005; 14: 1847-1850 [PMID: 16103423 DOI: 10.1158/1055-9965. epi-05-0456]
6. Wild CP. The exposome: from concept to utility. Int J Epidemiol 2012; 41: 24-32 [PMID: 22296988 DOI: 10.1093/ije/dyr236]
7. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-based Medicine. Levels of Evidence. Available from: URL: http://www.cebm.net/oxford-centreevidence-based-medicine-levels-evidence-march-2009
8. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-1260 [PMID: 2513902]
9. Noverr MC, Huffnagle GB. The 'microflora hypothesis' of allergic diseases. Clin Exp Allergy 2005; 35: 1511-1520 [PMID: 16393316 DOI: 10.1111/j.1365-2222.2005.02379.x]
10. Leong RW, Mitrev N, Ko Y. Hygiene Hypothesis: Is the Evidence the Same All Over the World? Dig Dis 2016; 34: 35-42 [PMID: 26982573 DOI: 10.1159/000442922]
11. Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol 2012; 107: 1399-1406 [PMID: 22777340 DOI: 10.1038/ajg.2012.196]
12. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 921-931 [PMID: 15813828 DOI: 10.1111/j.1365-2036.2005.02424.x]
13. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-1471 [PMID: 17120402 DOI: 10.4065/81.11.1462]
14. Mahid SS, Minor KS, Stromberg AJ, Galandiuk S. Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 431-438 [PMID: 17206676 DOI: 10.1002/ibd.20070]
15. Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004; 2: 41-48 [PMID: 15017631]
16. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552-557 [PMID: 12631668]
17. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-1099 [PMID: 11266373 DOI: 10.1053/gast.2001.23231]
18. Nunes T, Etchevers MJ, García-Sánchez V, Ginard D, Martí E, Barreiro-de Acosta M, Gomollón F, Arroyo M, Bastida G, Gonzalez B, Monfort D, García-Planella E, Figueroa C, Panés J, Sans M. Impact of Smoking Cessation on the Clinical Course of Crohn' s Disease Under Current Therapeutic Algorithms: A Multicenter Prospective Study. Am J Gastroenterol 2016; 111: 411-419 [PMID: 26856753 DOI: 10.1038/ajg.2015.401]
19. Nunes T, Etchevers MJ, Merino O, Gallego S, García-Sánchez V, Marín-Jiménez I, Menchén L, Barreiro-de Acosta M, Bastida G, García S, Gento E, Ginard D, Martí E, Gomollón F, Arroyo M, Monfort D, García-Planella E, Gonzalez B, Loras C, Agustí C, Figueroa C, Sans M. High smoking cessation rate in Crohn's disease patients after physician advice-The TABACROHN Study. J Crohns Colitis 2013; 7: 202-207 [PMID: 22626507 DOI: 10.1016/j.crohns.2012.04.011]
20. Boyko EJ, Koepsell TD, Perera DR, Inui TS. Risk of ulcerative colitis among former and current cigarette smokers. N Engl J Med 1987; 316: 707-710 [PMID: 3821808 DOI: 10.1056/nejm198703193161202]
21. Mokbel M, Carbonnel F, Beaugerie L, Gendre JP, Cosnes J. [Effect of smoking on the long-term course of ulcerative colitis]. Gastroenterol Clin Biol 1998; 22: 858-862 [PMID: 9881267]
22. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988; 23: 1147-1152 [PMID: 3247593]
23. Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, Odes S, Mouzas IA, Beltrami M, Langholz E, Stockbrügger R, Vatn M, Moum B. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007; 102: 1692-1701 [PMID: 17555460 DOI: 10.1111/j.15720241.2007.01265.x]
24. Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther 2015; 42: 391-405 [PMID: 26075832 DOI: 10.1111/apt.13276]
25. Benchimol EI, Mack DR, Guttmann A, Nguyen GC, To T, Mojaverian N, Quach P, Manuel DG. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol 2015; 110: 553-563 [PMID: 25756238 DOI: 10.1038/ajg.2015.52]
26. Soon IS, Molodecky NA, Rabi DM, Ghali WA, Barkema HW, Kaplan GG. The relationship between urban environment and the inflammatory bowel diseases: a systematic review and metaanalysis. BMC Gastroenterol 2012; 12: 51 [PMID: 22624994 DOI: 10.1186/1471-]
27. Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld R. The relationship between inflammatory bowel disease and socioeconomic variables. Am J Gastroenterol 2001; 96: 2117-2125 [PMID: 11467642 DOI: 10.1111/j.1572-]
28. Declercq C, Gower-Rousseau C, Vernier-Massouille G, Salleron J, Baldé M, Poirier G, Lerebours E, Dupas JL, Merle V, Marti R, Duhamel A, Cortot A, Salomez JL, Colombel JF. Mapping of inflammatory bowel disease in northern France: spatial variations and relation to affluence. Inflamm Bowel Dis 2010; 16: 807-812 [PMID: 19774647 DOI: 10.1002/ibd.21111]
29. Nerich V, Monnet E, Weill A, Vallier N, Vanbockstael V, Auleley GR, Balaire C, Dubost P, Rican S, Allemand H, Carbonnel F. Fine-scale geographic variations of inflammatory bowel disease in France: correlation with socioeconomic and house equipment variables. Inflamm Bowel Dis 2010; 16: 813-821 [PMID: 19902547 DOI: 10.1002/ibd.21122]
30. Zheng JJ, Zhu XS, Huangfu Z, Gao ZX, Guo ZR, Wang Z. Crohn's disease in mainland China: a systematic analysis of 50 years of research. Chin J Dig Dis 2005; 6: 175-181 [PMID: 16246226 DOI: 10.1111/j.1443-9573.2005.00227.x]
31. Hu D, Ren J, Wang G, Gu G, Liu S, Wu X, Chen J, Ren H, Hong Z, Li J. Geographic mapping of Crohn's disease and its relation to affluence in jiangsu province, an eastern coastal province of china. Gastroenterol Res Pract 2014; 2014: 590467 [PMID: 24839438 DOI: 10.1155/2014/590467]
32. Kaplan GG, Hubbard J, Korzenik J, Sands BE, Panaccione R, Ghosh S, Wheeler AJ, Villeneuve PJ. The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol 2010; 105: 2412-2419 [PMID: 20588264 DOI: 10.1038/ajg.2010.252]
33. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota: a link between exposure and inflammatory disease. Gut Microbes 2014; 5: 215-219 [PMID: 24637593 DOI: 10.4161/gmic.27251]
34. Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. Ambient air pollution correlates with hospitalizations for inflammatory bowel disease: an ecologic analysis. Inflamm Bowel Dis 2011; 17: 1138-1145 [PMID: 20806342 DOI: 10.1002/ibd.21455]
35. Masuyama H, Hiramatsu Y, Kunitomi M, Kudo T, MacDonald PN. Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. Mol Endocrinol 2000; 14: 421-428 [PMID: 10707959 DOI: 10.1210/mend.14.3.0424]
36. Soares A, Guieysse B, Jefferson B, Cartmell E, Lester JN. Nonylphenol in the environment: a critical review on occurrence, fate, toxicity and treatment in wastewaters. Environ Int 2008; 34: 1033-1049 [PMID: 18282600 DOI: 10.1016/j.envint.2008.01.004]
37. Vedani A, Smiesko M, Spreafico M, Peristera O, Dobler M. VirtualToxLab-in silico prediction of the toxic (endocrinedisrupting) potential of drugs, chemicals and natural products. Two years and 2,000 compounds of experience: a progress report. ALTEX 2009; 26: 167-176 [PMID: 19907904]
38. Wagner M, Schlüsener MP, Ternes TA, Oehlmann J. Identification of putative steroid receptor antagonists in bottled water: combining bioassays and high-resolution mass spectrometry. PLoS One 2013; 8: e72472 [PMID: 24015248 DOI: 10.1371/journal.pone.0072472]
39. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004; 229: 1136-1142 [PMID: 15564440]
40. Cantorna MT, Mahon BD. D-hormone and the immune system. J Rheumatol Suppl 2005; 76: 11-20 [PMID: 16142846]
41. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80: 1717S-1720S [PMID: 15585793]
42. Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012; 142: 482-489 [PMID: 22155183 DOI: 10.1053/j.gastro.2011.11.040]
43. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648-2652 [PMID: 11053501]
44. Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2015; 21: 2708-2717 [PMID: 26348447 DOI: 10.1097/mib.0000000000000546]
45. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007; 8: 5 [PMID: 17397543 DOI: 10.1186/1471-2172-8-5]
46. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386-2392 [PMID: 14500760 DOI: 10.1210/me.2003-0281]
47. Froicu M, Zhu Y, Cantorna MT. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 2006; 117: 310-318 [PMID: 16476050 DOI: 10.1111/j.1365-2567.2005.02290.x]
48. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678S-1688S [PMID: 15585788]
49. Holmes EA, Xiang F, Lucas RM. Variation in incidence of pediatric Crohn's disease in relation to latitude and ambient ultraviolet radiation: a systematic review and analysis. Inflamm Bowel Dis 2015; 21: 809-817 [PMID: 25789921 DOI: 10.1097/mib.0000000000000320]
50. Hughes DJ, McManus R, Neary P, O'morain C, O'sullivan M. Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case-control study. Eur J Gastroenterol Hepatol 2011; 23: 807-812 [PMID: 21818054 DOI: 10.1097/MEG.0b013e328349283e]
51. Jørgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, Bartels LE, Kelsen J, Christensen LA, Dahlerup JF. Clinical trial: vitamin D3 treatment in Crohn's disease-a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 377-383 [PMID: 20491740 DOI: 10.1111/j.1365-2036.2010.04355.x]
52. Miheller P, Muzes G, Hritz I, Lakatos G, Pregun I, Lakatos PL, Herszényi L, Tulassay Z. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009; 15: 1656-1662 [PMID: 19408329 DOI: 10.1002/ibd.20947]
53. Naderi N, Farnood A, Habibi M, Derakhshan F, Balaii H, Motahari Z, Agah MR, Firouzi F, Rad MG, Aghazadeh R, Zojaji H, Zali MR. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008; 23: 1816-1822 [PMID: 18752562 DOI: 10.1111/j.1440-1746.2008.05525.x]
54. Narula N, Marshall JK. Management of inflammatory bowel disease with vitamin D: beyond bone health. J Crohns Colitis 2012; 6: 397-404 [PMID: 22398052 DOI: 10.1016/j.crohns.2011.10.015]
55. Nerich V, Jantchou P, Boutron-Ruault MC, Monnet E, Weill A, Vanbockstael V, Auleley GR, Balaire C, Dubost P, Rican S, Allemand H, Carbonnel F. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther 2011; 33: 940-945 [PMID: 21332762 DOI: 10.1111/j.1365-2036.2011.04601.x]
56. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006; 12: 1162-1174 [PMID: 17119391 DOI: 10.1097/01. mib.0000236929.74040.b]
57. Raffner Basson A, Swart R, Jordaan E, Mazinu M, Watermeyer G. Vitamin D Deficiency Increases the Risk for Moderate to Severe Disease Activity in Crohn's Disease Patients in South Africa, Measured by the Harvey Bradshaw Index. J Am Coll Nutr 2016; 35: 163-174 [PMID: 26430776 DOI: 10.1080/07315724.2015.1039665]
58. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000; 47: 211-214 [PMID: 10896912]
59. Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, Issa M. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr 2011; 35: 308-316 [PMID: 21527593 DOI: 10.1177/0148607110381267]
60. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn's patients. Clin Transl Gastroenterol 2013; 4: e33 [PMID: 23594800 DOI: 10.1038/ctg.2013.1]
61. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005; 35: 217-224 [PMID: 15593122 DOI: 10.1002/eji.200425491]
62. Khalili H, Huang ES, Ananthakrishnan AN, Higuchi L, Richter JM, Fuchs CS, Chan AT. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012; 61: 1686-1692 [PMID: 22241842 DOI: 10.1136/gutjnl-2011-301574]
63. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519 [PMID: 12583961 DOI: 10.1016/s0140-6736(03)12489-0]
64. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from highthroughput sequencing. Gastroenterology 2011; 140: 1713-1719 [PMID: 21530737 DOI: 10.1053/j.gastro.2011.02.011]
65. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science 2009; 326: 1694-1697 [PMID: 19892944 DOI: 10.1126/science.1177486]
66. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118: 511-521 [PMID: 16882802 DOI: 10.1542/peds.2005-2824]
67. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]
68. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115-1118 [PMID: 11352068]
69. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407 [PMID: 16819502 DOI: 10.1038/ncpgasthep0528]
70. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140: 1720-1728 [PMID: 21530738 DOI: 10.1053/j.gastro.2011.01.054]
71. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72]
72. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104]
73. Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the faecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279-284 [PMID: 3972275]
74. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-774 [PMID: 1681159]
75. Lepage P, Seksik P, Sutren M, de la Cochetière MF, Jian R, Marteau P, Doré J. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 2005; 11: 473-480 [PMID: 15867587]
76. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]
77. Scanlan PD, Shanahan F, O'Mahony C, Marchesi JR. Cultureindependent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 2006; 44: 3980-3988 [PMID: 16988018 DOI: 10.1128/jcm.00312-06]
78. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006; 55: 1141-1149 [PMID: 16849736 DOI: 10.1099/jmm.0.46498-0]
79. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-810 [PMID: 17943116 DOI: 10.1038/nature06244]
80. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 1183-1189 [PMID: 19235886 DOI: 10.1002/ibd.20903]
81. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736 [PMID: 18936492 DOI: 10.1073/pnas.0804812105]
82. Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 2014; 20: 978-986 [PMID: 24788220 DOI: 10.1097/mib.0000000000000036]
83. Bullock NR, Booth JC, Gibson GR. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Curr Issues Intest Microbiol 2004; 5: 59-64 [PMID: 15460067]
84. Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, Guarner F, Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 151-161 [PMID: 23725320 DOI: 10.1111/apt.12365]
85. Zaph C, Du Y, Saenz SA, Nair MG, Perrigoue JG, Taylor BC, Troy AE, Kobuley DE, Kastelein RA, Cua DJ, Yu Y, Artis D. Commensaldependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J Exp Med 2008; 205: 2191-2198 [PMID: 18762568 DOI: 10.1084/jem.20080720]
86. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27 [PMID: 16903903 DOI: 10.1111/j.0105-2896.2006.00427.x]
87. Ostman S, Rask C, Wold AE, Hultkrantz S, Telemo E. Impaired regulatory T cell function in germ-free mice. Eur J Immunol 2006; 36: 2336-2346 [PMID: 16897813 DOI: 10.1002/eji.200535244]
88. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453: 236-240 [PMID: 18368049 DOI: 10.1038/nature06878]
89. Adeeti Chiplunker ANA, Dawn B. Beaulieu, Amar S. Naik, Yelena Zadvornova, Susan Skaros, Kathryn Johnson, Lilani P. Perera, David G. Binion, Mazen Issa. S1145 Long-Term Impact of Clostridium difficile On Inflammatory Bowel Disease. Gastroenterology 2009; 136: Page A-199 [DOI: 10.1016/S0016-5085(09)60894-5]
90. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-210 [PMID: 17905821 DOI: 10.1136/gut.2007.128231]
91. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short-and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501 [PMID: 19361507 DOI: 10.1053/j.gastro.2009.04.001]
92. Jess T, Simonsen J, Nielsen NM, Jørgensen KT, Bager P, Ethelberg S, Frisch M. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut 2011; 60: 318-324 [PMID: 21193449 DOI: 10.1136/gut.2010.223396]
93. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415-420 [PMID: 19255850 DOI: 10.1007/s10620-009-0749-9]
94. Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. Mycobacterium avium subspecies paratuberculosis causes Crohn' s disease in some inflammatory bowel disease patients. World J Gastroenterol 2014; 20: 7403-7415 [PMID: 24966610 DOI: 10.3748/wjg.v20.i23.7403]
95. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344 [PMID: 17368233 DOI: 10.1016/j.cgh.2006.12.027]
96. Bernstein CN, Rawsthorne P, Blanchard JF. Population-based casecontrol study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 759-762 [PMID: 17230540 DOI: 10.1002/ibd.20089]
97. Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: is there a link? World J Gastroenterol 2006; 12: 4813-4818 [PMID: 16937462]
98. Greenberg R, Greenwald B, Roth JS, Ioffe O, Cross R. Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. Dig Dis Sci 2008; 53: 760-764 [PMID: 17717741 DOI: 10.1007/s10620-007-9935-9]
99. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28: 365-373 [PMID: 15104299]
100. Kim JJ, Simpson N, Klipfel N, Debose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010; 55: 1059-1065 [PMID: 20112061 DOI: 10.1007/s10620-010-1126-4]
101. Kojima T, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H. Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol 2006; 41: 706-711 [PMID: 16716970 DOI: 10.1080/0 0365520500408584]
102. Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, Dandekar S. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol 2011; 50: 31-36 [PMID: 21035384 DOI: 10.1016/j.jcv.2010.09.011]
103. Schunter MO, Walles T, Fritz P, Meyding-Lamadé U, Thon KP, Fellermann K, Stange EF, Lamadé W. Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections. J Crohns Colitis 2007; 1: 41-46 [PMID: 21172183 DOI: 10.1016/j.crohns.2007.06.004]
104. Spieker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol 2000; 157: 51-57 [PMID: 10880375 DOI: 10.1016/s0002-9440(10)64516-6]
105. Wakefield AJ, Fox JD, Sawyerr AM, Taylor JE, Sweenie CH, Smith M, Emery VC, Hudson M, Tedder RS, Pounder RE. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol 1992; 38: 183-190 [PMID: 1287131]
106. Wang W, Jovel J, Halloran B, Wine E, Patterson J, Ford G, O'Keefe S, Meng B, Song D, Zhang Y, Tian Z, Wasilenko ST, Rahbari M, Reza S, Mitchell T, Jordan T, Carpenter E, Madsen K, Fedorak R, Dielemann LA, Ka-Shu Wong G, Mason AL. Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. Inflamm Bowel Dis 2015; 21: 1419-1427 [PMID: 25939040 DOI: 10.1097/mib.0000000000000344]
107. Yanai H, Shimizu N, Nagasaki S, Mitani N, Okita K. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1582-1586 [PMID: 10364028 DOI: 10.1111/j.1572-0241.1999.01148.x]
108. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2009; 15: 128-133 [PMID: 18680198 DOI: 10.1002/ibd.20633]
109. Ramanan D, Bowcutt R, Lee SC, Tang MS, Kurtz ZD, Ding Y, Honda K, Gause WC, Blaser MJ, Bonneau RA, Lim YA, Loke P, Cadwell K. Helminth infection promotes colonization resistance via type 2 immunity. Science 2016; 352: 608-612 [PMID: 27080105 DOI: 10.1126/science.aaf3229]
110. Kabeerdoss J, Pugazhendhi S, Subramanian V, Binder HJ, Ramakrishna BS. Exposure to hookworms in patients with Crohn's disease: a case-control study. Aliment Pharmacol Ther 2011; 34: 923-930 [PMID: 21848628 DOI: 10.1111/j.1365-2036.2011.04824.x]
111. Setiawan T, Metwali A, Blum AM, Ince MN, Urban JF, Elliott DE, Weinstock JV. Heligmosomoides polygyrus promotes regulatory T-cell cytokine production in the murine normal distal intestine. Infect Immun 2007; 75: 4655-4663 [PMID: 17606601 DOI: 10.1128/iai.00358-07]
112. Weinstock JV, Elliott DE. Helminth infections decrease host susceptibility to immune-mediated diseases. J Immunol 2014; 193: 3239-3247 [PMID: 25240019 DOI: 10.4049/jimmunol.1400927]
113. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther 2013; 38: 255-263 [PMID: 23730956 DOI: 10.1111/apt.12366]
114. Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev 2014; (1): CD009400 [PMID: 24442917 DOI: 10.1002/14651858.CD009400.pub2]
115. Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 137-151 [PMID: 19462428 DOI: 10.1002/ibd.20968]
116. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fatinduced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature 2012; 487: 104-108 [PMID: 22722865 DOI: 10.1038/nature11225]
117. Ma X, Torbenson M, Hamad AR, Soloski MJ, Li Z. High-fat diet modulates non-CD1d-restricted natural killer T cells and regulatory T cells in mouse colon and exacerbates experimental colitis. Clin Exp Immunol 2008; 151: 130-138 [PMID: 17991290 DOI: 10.1111/j.1365-2249.2007.03530.x]
118. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011; 106: 563-573 [PMID: 21468064 DOI: 10.1038/ajg.2011.44]
119. Bassaganya-Riera J, DiGuardo M, Viladomiu M, de Horna A, Sanchez S, Einerhand AW, Sanders L, Hontecillas R. Soluble fibers and resistant starch ameliorate disease activity in interleukin-10-deficient mice with inflammatory bowel disease. J Nutr 2011; 141: 1318-1325 [PMID: 21562241 DOI: 10.3945/jn.111.139022]
120. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013; 145: 970-977 [PMID: 23912083 DOI: 10.1053/j.gastro.2013.07.050]
121. Rodríguez-Cabezas ME, Gálvez J, Camuesco D, Lorente MD, Concha A, Martinez-Augustin O, Redondo L, Zarzuelo A. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr 2003; 22: 463-471 [PMID: 14512034]
122. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné JJ, Moles J, Gomollón F, Gassull MA. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433 [PMID: 10022641 DOI: 10.1111/j.1572-0241.1999.872-a.x]
123. Heath-Pagliuso S, Rogers WJ, Tullis K, Seidel SD, Cenijn PH, Brouwer A, Denison MS. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 1998; 37: 11508-11515 [PMID: 9708986 DOI: 10.1021/bi980087p]
124. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D'Angelo C, Massi-Benedetti C, Fallarino F, Carvalho A, Puccetti P, Romani L. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39: 372-385 [PMID: 23973224 DOI: 10.1016/j.immuni.2013.08.003]
125. Ballegaard M, Bjergstrøm A, Brøndum S, Hylander E, Jensen L, Ladefoged K. Self-reported food intolerance in chronic inflammatory bowel disease. Scand J Gastroenterol 1997; 32: 569-571 [PMID: 9200289]
126. Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006; 21: 1609-1614 [PMID: 16928225 DOI: 10.1111/j.1440-1746.2006.04294.x]
127. González-Huix F, Fernández-Bañares F, Esteve-Comas M, Abad-Lacruz A, Cabré E, Acero D, Figa M, Guilera M, Humbert P, de León R. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88: 227-232 [PMID: 8424426]
128. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, Takahashi H, Takahashi S, Kinouchi Y, Hiwatashi N, Funayama Y, Sasaki I, Tsuji I, Shimosegawa T. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn' s disease: A randomized-controlled trial. Aliment Pharmacol Ther 2006; 24: 1333-1340 [PMID: 17059514 DOI: 10.1111/j.1365-2036.2006.03120.x]
129. Bentz S, Hausmann M, Piberger H, Kellermeier S, Paul S, Held L, Falk W, Obermeier F, Fried M, Schölmerich J, Rogler G. Clinical relevance of IgG antibodies against food antigens in Crohn's disease: a double-blind cross-over diet intervention study. Digestion 2010; 81: 252-264 [PMID: 20130407 DOI: 10.1159/000264649]
130. Becker HM, Bertschinger MM, Rogler G. Microparticles and their impact on intestinal immunity. Dig Dis 2012; 30 Suppl 3: 47-54 [PMID: 23295692 DOI: 10.1159/000342602]
131. Pineton de Chambrun G, Body-Malapel M, Frey-Wagner I, Djouina M, Deknuydt F, Atrott K, Esquerre N, Altare F, Neut C, Arrieta MC, Kanneganti TD, Rogler G, Colombel JF, Cortot A, Desreumaux P, Vignal C. Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunol 2014; 7: 589-601 [PMID: 24129165 DOI: 10.1038/mi.2013.78]
132. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107: 14691-14696 [PMID: 20679230 DOI: 10.1073/pnas.1005963107]
133. Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS, Schlegel ML, Tucker TA, Schrenzel MD, Knight R, Gordon JI. Evolution of mammals and their gut microbes. Science 2008; 320: 1647-1651 [PMID: 18497261 DOI: 10.1126/science.1155725]
134. Muegge BD, Kuczynski J, Knights D, Clemente JC, González A, Fontana L, Henrissat B, Knight R, Gordon JI. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011; 332: 970-974 [PMID: 21596990 DOI: 10.1126/science.1198719]
135. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 2011; 65: 411-429 [PMID: 21682646 DOI: 10.1146/annurev-micro-]
136. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108 [PMID: 21885731 DOI: 10.1126/science.1208344]
137. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 751-757 [PMID: 15626893]
138. Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 1946-1948 [PMID: 10950040 DOI: 10.1111/j.1572-0241.2000.02263.x]
139. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, Bjornsson E, Bjarnason I. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202 [PMID: 16469680]
140. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci 2006; 51: 168-172 [PMID: 16416231 DOI: 10.1007/s10620-006-3103-5]
141. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004; 19: 755-764 [PMID: 15043516 DOI: 10.1111/j.1365-2036.2004.01907.x]
142. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 352-356 [PMID: 15475742]
143. Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002; 97: 910-914 [PMID: 12008668 DOI: 10.1111/j.1572-0241.2002.05608.x]
144. Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhoer T, Lichtenberger C, Vogelsang H. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003; 17: 1371-1380 [PMID: 12786631]
145. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol 2008; 43: 961-966 [PMID: 19086166]
146. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol 2011; 106: 2133-2142 [PMID: 21912437 DOI: 10.1038/ajg.2011.304]
147. Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, Shaw S, Van Kruiningen H, Colombel JF, Atreja A. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014; 109: 1728-1738 [PMID: 25223575 DOI: 10.1038/ajg.2014.246]
148. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621 [PMID: 7768364]
149. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, Aerden I, De Hertogh G, Geboes K, Hiele M, D'Hoore A, Penninckx F. Ornidazole for prophylaxis of postoperative Crohn' s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861 [PMID: 15825069]
150. Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2394-2400 [PMID: 18684177 DOI: 10.1111/j.1572-0241.2008.02064.x]
151. Khalili H, Higuchi LM, Ananthakrishnan AN, Richter JM, Feskanich D, Fuchs CS, Chan AT. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut 2013; 62: 1153-1159 [PMID: 22619368 DOI: 10.1136/gutjnl-2012-302362]
152. Khalili H, Higuchi LM, Ananthakrishnan AN, Manson JE, Feskanich D, Richter JM, Fuchs CS, Chan AT. Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. Gastroenterology 2012; 143: 1199-1206 [PMID: 22841783 DOI: 10.1053/j.gastro.2012.07.096]
153. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 1999; 45: 218-222 [PMID: 10403733]
154. Kane SV, Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1193-1196 [PMID: 18177456 DOI: 10.1111/j.1572-0241.2007.01700.x]
155. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1998; 114: 1143-1150 [PMID: 9618650]
156. Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases. Ann N Y Acad Sci 2006; 1089: 538-547 [PMID: 17261796 DOI: 10.1196/annals.1386.043]
157. Sternberg EM, Chrousos GP, Wilder RL, Gold PW. The stress response and the regulation of inflammatory disease. Ann Intern Med 1992; 117: 854-866 [PMID: 1416562]
158. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010; 105: 1994-2002 [PMID: 20372115 DOI: 10.1038/ajg.2010.140]
159. Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008; 57: 1386-1392 [PMID: 18390994 DOI: 10.1136/gut.2007.134817]
160. Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD, Harbus MD, Christos PJ, Brown RP, Scherl EJ. The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial. Inflamm Bowel Dis 2015; 21: 2886-2896 [PMID: 26426148 DOI: 10.1097/mib.0000000000000568]
161. Boye B, Lundin KE, Jantschek G, Leganger S, Mokleby K, Tangen T, Jantschek I, Pripp AH, Wojniusz S, Dahlstroem A, Rivenes AC, Benninghoven D, Hausken T, Roseth A, Kunzendorf S, Wilhelmsen I, Sharpe M, Blomhoff S, Malt UF, Jahnsen J. INSPIRE study: does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or Crohn's disease? A randomized controlled trial. Inflamm Bowel Dis 2011; 17: 1863-1873 [PMID: 21287660 DOI: 10.1002/ibd.21575]
162. Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011; (2): CD006913 [PMID: 21328288 DOI: 10.1002/14651858.CD006913.pub2]
163. Dickstein JB, Moldofsky H. Sleep, cytokines and immune function. Sleep Med Rev 1999; 3: 219-228 [PMID: 15310476]
164. Opp MR. Cytokines and sleep. Sleep Med Rev 2005; 9: 355-364 [PMID: 16102986 DOI: 10.1016/j.smrv.2005.01.002]
165. Shearer WT, Reuben JM, Mullington JM, Price NJ, Lee BN, Smith EO, Szuba MP, Van Dongen HP, Dinges DF. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001; 107: 165-170 [PMID: 11150007 DOI: 10.1067/mai.2001.112270]
166. Gamaldo CE, Shaikh AK, McArthur JC. The sleep-immunity relationship. Neurol Clin 2012; 30: 1313-1343 [PMID: 23099140 DOI: 10.1016/j.ncl.2012.08.007]
167. Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. Inflamm Res 2007; 56: 51-57 [PMID: 17431741 DOI: 10.1007/s00011-006-]
168. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997; 82: 1313-1316 [PMID: 9141509 DOI: 10.1210/jcem.82.5.3950]
169. Zisapel N. Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci 2007; 64: 1174-1186 [PMID: 17364142 DOI: 10.1007/s00018-007-6529-9]
170. Ali T, Orr WC. Sleep disturbances and inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 1986-1995 [PMID: 25025716 DOI: 10.1097/mib.0000000000000108]
171. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006; 166: 1756-1762 [PMID: 16983055 DOI: 10.1001/archinte.166.16.1756]
172. Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A. An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med 2006; 2: 409-416 [PMID: 17557469]
173. Tang Y, Preuss F, Turek FW, Jakate S, Keshavarzian A. Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. Sleep Med 2009; 10: 597-603 [PMID: 19403332 DOI: 10.1016/j.sleep.2008.12.009]
174. Graff LA, Vincent N, Walker JR, Clara I, Carr R, Ediger J, Miller N, Rogala L, Rawsthorne P, Lix L, Bernstein CN. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1882-1889 [PMID: 21830266 DOI: 10.1002/ibd.21580]
175. Ranjbaran Z, Keefer L, Farhadi A, Stepanski E, Sedghi S, Keshavarzian A. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol 2007; 22: 1748-1753 [PMID: 17914945 DOI: 10.1111/j.1440-1746.2006.04820.x]
176. Ali T, Choe J, Awab A, Wagener TL, Orr WC. Sleep, immunity and inflammation in gastrointestinal disorders. World J Gastroenterol 2013; 19: 9231-9239 [PMID: 24409051 DOI: 10.3748/wjg.v19. i48.9231]
177. Ali T, Madhoun MF, Orr WC, Rubin DT. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis 2013; 19: 2440-2443 [PMID: 23945186 DOI: 10.1097/MIB.0b013e3182a0ea54]
178. Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013; 11: 965-971 [PMID: 23376797 DOI: 10.1016/j.cgh.2013.01.021]
179. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911-920 [PMID: 12239261 DOI: 10.1056/NEJMra020100]
180. Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, Yzet T, Lerebours E, Dupas JL, Debeugny S, Salomez JL, Cortot A, Colombel JF. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005; 54: 357-363 [PMID: 15710983 DOI: 10.1136/gut.2004.054353]
181. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol 1987; 22: 1009-1024 [PMID: 3685876]
182. Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P. Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort. J Crohns Colitis 2011; 5: 577-584 [PMID: 22115378 DOI: 10.1016/j.crohns.2011.05.010]
183. Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P. Pineton de Chambrun G. UEG Week 2015 Poster Presentations. United Eur Gastroenterol J 2015; 3 (5 Suppl): 146-687 [DOI: 10.1177/2050640615601623]
184. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 2008; 14: 165-173 [PMID: 18186549]
185. Goldman AS. The immune system in human milk and the developing infant. Breastfeed Med 2007; 2: 195-204 [PMID: 18081456 DOI: 10.1089/bfm.2007.0024]
186. Brock JH. The physiology of lactoferrin. Biochem Cell Biol 2002; 80: 1-6 [PMID: 11908632]
187. Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr 2004; 80: 1342-1352 [PMID: 15531685]
188. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case-control study. Am J Epidemiol 1990; 132: 1111-1119 [PMID: 2260543]
189. Thompson NP, Montgomery SM, Wadsworth ME, Pounder RE, Wakefield AJ. Early determinants of inflammatory bowel disease: use of two national longitudinal birth cohorts. Eur J Gastroenterol Hepatol 2000; 12: 25-30 [PMID: 10656206]
190. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 2003; 124: 40-46 [PMID: 12512028 DOI: 10.1053/gast.2003.50021]
191. Koutroubakis IE, Vlachonikolis IG, Kapsoritakis A, Spanoudakis S, Roussomoustakaki M, Mouzas IA, Kouroumalis EA, Manousos ON. Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: case-controlled study in Crete. Dis Colon Rectum 1999; 42: 225-230 [PMID: 10211500]
192. Reif S, Lavy A, Keter D, Broide E, Niv Y, Halak A, Ron Y, Eliakim R, Odes S, Patz J, Fich A, Villa Y, Arber N, Gilat T. Appendectomy is more frequent but not a risk factor in Crohn's disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 829-832 [PMID: 11280559 DOI: 10.1111/j.1572-0241.2001.03529.x]
193. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J. The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol 2008; 103: 2925-2931 [PMID: 18775018 DOI: 10.1111/j.1572-0241.2008.02118.x]
194. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996; 184: 707-715 [PMID: 8760824]
195. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med 2001; 344: 808-814 [PMID: 11248156 DOI: 10.1056/nejm200103153441104]
196. Russel MG, Dorant E, Brummer RJ, van de Kruijs MA, Muris JW, Bergers JM, Goedhard J, Stockbrügger RW. Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997; 113: 377-382 [PMID: 9247453]
197. Bartel G, Weiss I, Turetschek K, Schima W, Püspök A, Waldhoer T, Gasche C. Ingested matter affects intestinal lesions in Crohn's disease. Inflamm Bowel Dis 2008; 14: 374-382 [PMID: 17932967 DOI: 10.1002/ibd.20295]
198. Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16: 2484-2495 [PMID: 20503448]
199. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7: 473-487 [PMID: 25525379 DOI: 10.2147/ceg.s27530]
200. Hanai H, Kanauchi O, Mitsuyama K, Andoh A, Takeuchi K, Takayuki I, Araki Y, Fujiyama Y, Toyonaga A, Sata M, Kojima A, Fukuda M, Bamba T. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004; 13: 643-647 [PMID: 15067363]
201. Lev-Tzion R, Griffiths AM, Leder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2014; (2): CD006320 [PMID: 24585498 DOI: 10.1002/14651858.CD006320.pub4]
202. Lomer MC, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE, Vicary FR, Jenkins AP, Fidler H, Harvey RS, Ellis R, McNair A, Ainley CC, Thompson RP, Powell JJ. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2005; 17: 377-384 [PMID: 15716665]
203. Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur J Gastroenterol Hepatol 2001; 13: 101-106 [PMID: 11246607]
204. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109.e6 [PMID: 25857665 DOI: 10.1053/j.gastro.2015.04.001]
205. Nikfar S, Ehteshami-Ashar S, Rahimi R, Abdollahi M. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clin Ther 2010; 32: 2304-2315 [PMID: 21353102 DOI: 10.1016/j.clinthera.2011.01.004]
206. Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J Crohns Colitis 2014; 8: 1498-1505 [PMID: 24972748 DOI: 10.1016/j.crohns.2014.06.001]
207. Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease. Br Med J (Clin Res Ed) 1987; 295: 517-520 [PMID: 2822203]
208. Turner D, Steinhart AH, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (3): CD006443 [PMID: 17636844 DOI: 10.1002/14651858.CD006443.pub2]
209. Wright R, Truelove SC. A controlled therapeutic trial of various diets in ulcerative colitis. Br Med J 1965; 2: 138-141 [PMID: 14304053]
210. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007; (1): CD000542 [PMID: 17253452 DOI: 10.1002/14651858.CD000542.pub2]
211. Mukherjee B, Ahn J, Gruber SB, Chatterjee N. Testing geneenvironment interaction in large-scale case-control association studies: possible choices and comparisons. Am J Epidemiol 2012; 175: 177-190 [PMID: 22199027 DOI: 10.1093/aje/kwr367]
212. Wang Y, Li D, Wei P. Powerful Tukey's One Degree-of-Freedom Test for Detecting Gene-Gene and Gene-Environment Interactions. Cancer Inform 2015; 14: 209-218 [PMID: 26064040 DOI: 10.4137/cin.s17305]
213. Wild CP, Scalbert A, Herceg Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ Mol Mutagen 2013; 54: 480-499 [PMID: 23681765 DOI: 10.1002/em.21777]
214. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172-1187 [PMID: 22424228 DOI: 10.1016/j.cell.2012.02.005]